Published in final edited form as:

Horm Cancer. 2015 December ; 6(0): 237–246. doi:10.1007/s12672-015-0235-0.

Alcohol Consumption and Risk of Breast Cancer by Tumor Receptor Expression

Jun Wang¹, Xuehong Zhang², Andrew H. Beck³, Laura C. Collins³, Wendy Y. Chen^{2,4}, Rulla M. Tamimi^{2,5}, Aditi Hazra^{2,5}, Myles Brown⁴, Bernard Rosner^{2,6}, and Susan E. Hankinson^{1,2,5}

¹Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts Amherst, 715 N Pleasant Street, Amherst, MA 01003, USA

²Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA

³Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA

⁴Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA

⁵Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA

⁶Department of Biostatistics, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA

Abstract

In epidemiologic studies, alcohol consumption appears more strongly associated with risk of estrogen receptor (ER)-positive than ER-negative breast cancer. However, this association has not been assessed by other potentially relevant tumor markers, such as androgen receptor (AR) or insulin receptor (IR). In the prospective Nurses' Health Study cohort, we evaluated alcohol consumption and breast cancer risk by individual tumor marker expression (i.e. ER, Progesterone Receptor [PR], AR and IR) while controlling for other markers and also assessed the joint effect of these receptors. During 26 years follow-up of 106,037 women, 2,552 invasive breast cancers contributed to the analysis. When all four markers were considered simultaneously, no significant heterogeneity of the alcohol and breast cancer association was observed by any of the markers. However, each increment in one drink per day was associated with 10% (95% confidence interval [CI] = 4%, 15%) and 9% (95%CI = 4%, 15%) increased risk of AR-positive and ER-positive breast cancer, respectively while no increased risk was observed among AR-negative or ER-negative tumors. The association was independent of PR and IR expression. Assessment of the joint expression of hormone receptors revealed a significantly increased risk among AR+/ER+/PR+ (hazard ratio [HR] per drink/day = 1.11, 95%CI = 1.06, 1.17) but not in other subgroups (e.g. AR-/ER-/PR-: HR = 0.99; 95%CI = 0.88, 1.12). Our data suggest that the alcohol and breast

Corresponding Author: Jun Wang, Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts Amherst, 715 North Pleasant Street, Amherst, MA 01003, Tel: 413-545-0845, Fax: 413-545-1645, junw@schoolph.umass.edu.

Conflict of Interest: The authors declare that they have no conflict of interest.

cancer association may be more pronounced among ER-positive and/or AR-positive breast tumors. However, our data do not support an important role of IR in the association.

Keywords

Alcohol; Breast Cancer; Epidemiology; Prospective; Androgen Receptor; Insulin Receptor

Introduction

Alcohol consumption, even low to moderate intake, is a consistent risk factor for breast cancer in epidemiologic studies, with approximately 10–20% increase in risk for three to six drinks per week compared to non-drinkers [1–3]. In prospective cohort studies, similar or stronger positive associations compared to all breast cancer cases combined has been reported for tumors expressing estrogen receptor (ER) or both ER and progesterone receptor (PR) [4–6,2]. Moreover, alcohol consumption increases circulating estrogen levels [7–11].

However, the alcohol and breast cancer association has never been evaluated according to other potential biomarkers in breast cancer, such as the androgen receptor (AR) or the insulin receptor (IR). AR has important physiological effects in normal breast development, is expressed in >70% of malignant breast tissue [12,13], and has been reported as a favorable prognostic factor for breast cancer survival [14]. Although studies addressing the role of AR in breast cancer etiology are limited, pre-diagnostic circulating levels of androgens are consistently positively associated with breast cancer risk [15–17]. Also, alcohol intake has been positively correlated with circulating androgen levels, particularly dehydroepiandrosterone sulfate, in controlled intervention trials and cross-sectional studies [18,7–11]. IR has also been hypothesized to be involved in breast cancer as it is over-expressed in the majority of breast cancer [19,20], with increasing supporting data from experimental and clinical studies [21]. Interestingly, while alcohol consumption is positively correlated with circulating androgens, it is associated with improved insulin sensitivity and decreased circulating insulin in both observational and controlled diet studies [22–24]. Furthermore, recent prospective studies of circulating pre-diagnostic insulin or c-peptide and breast cancer risk suggest a positive association [25,26], although no overall significant association was found in a meta-analysis of earlier prospective studies [27].

Previous studies suggest that breast cancer risk profiles vary according to tumor marker expression [28,29]. Therefore, we proposed to evaluate alcohol consumption and breast cancer risk by several hormone receptors, individually and simultaneously, in the Nurses' Health Study (NHS) cohort.

Material and Methods

Study Population

Details of the study design of the NHS and the study population have been reported elsewhere [30,2]. Briefly, the NHS was established in 1976 when 121,701 U.S. female registered nurses, aged 30–55 years, completed an initial mailed questionnaire. The cohort has been followed biennially by mailed questionnaire to update information on exposure

status and ascertain newly diagnosed diseases. The analytic period started in 1980 when alcohol consumption was first assessed. A total of 106,037 entered the analysis after exclusion of participants who developed cancer or died before 1980 (N = 5,652) and those with missing alcohol data at baseline and during follow-up (N = 10,012). The study was approved by the Committee on the Use of Human Subjects in Research at the Brigham and Women's Hospital. Informed consent was obtained from all women participating in the study.

Assessment of Alcohol Consumption and Covariates

The assessment of alcohol consumption has been described in detail elsewhere [2]. In brief, information was first collected in 1980 when participants reported their average frequency of intake for each alcoholic beverage (i.e. beer, wine, and liquor) during the previous 12 months through a semi-quantitative food frequency questionnaire, and updated in 1984, 1986, 1990, 1994, 1998 and 2002. Alcohol intake (grams per day) was calculated as the sum of the daily number of drinks multiplied by the average alcohol content of each type of alcoholic beverage (12.8 g of alcohol per beer, 11.0 g per glass of wine, and 14.0 g per serving of liquor). We then calculated cumulative average intake by averaging alcohol consumption over time using all available information beginning in 1980; we considered this the primary exposure variable in our analysis because it was the exposure definition mostly strongly associated with breast cancer risk in our prior analysis [2]. Alcohol intake ascertained from a self-report food frequency questionnaire was found to be very similar with that calculated from detailed diet records in a sample of 173 women in the NHS cohort (Spearman $r = 0.90$) [31].

Covariates data, such as age at menarche, age at first birth, parity, family history of breast cancer, diagnosis of benign breast disease, weight, smoking, menopausal status and menopausal hormone therapy (MHT) use was obtained from the NHS questionnaire at baseline or the subsequent biennial questionnaires.

Ascertainment of Breast Cancer Cases

Breast cancer cases were identified through self-report on biennial questionnaires. All women reporting incident diagnoses of breast cancer were asked for permission to review their medical records; for cases for which pathology reports were obtained, cases were confirmed by medical record review (99%). Deaths were ascertained through reporting by next of kin or postal authorities or searching the National Death Index, and approximately 98% of deaths in the NHS have been identified by these methods [32,33].

Tissue Microarrays and Immunohistochemical Analysis

Details of breast cancer tissue block collection and tissue microarray (TMA) construction have been described previously [34]. Briefly, we collected archived formalin-fixed paraffin-embedded breast cancer blocks from participants with incident breast cancers diagnosed 1980–2006. Of 7,964 invasive tumors that were eligible for block collection, 4,054 (51%) were finally included in TMAs; of blocks not included in TMAs, the majority had been destroyed by the hospital or there was insufficient tumor in the block for TMA construction. TMAs were constructed in the Dana Farber Harvard Cancer Center Tissue Microarray Core

Facility, Boston, Massachusetts. Three cores, 0.6 mm in diameter, were obtained from each breast cancer sample and inserted into the recipient TMA blocks.

We performed immunohistochemical (IHC) assessments for AR, ER, PR and IR on 5µm paraffin sections cut from the TMA blocks [34,13] (Supplementary Table 1) and completed the assessment for 3598 cases. Cases included in TMAs contributing to this analysis were very similar to all eligible invasive cases in terms of demographics, breast cancer risk factors and tumor characteristics (Supplementary Table 2). For AR, ER, and PR, TMA slides were read by an independent pathologist; tumor cells that showed any nuclear staining of AR, ER or PR (1% of nuclei staining positive) were considered AR, ER or PR positive, respectively. AR expression was determined by TMA slides exclusively while ER and PR were determined primarily from TMA slides and secondarily from pathology reports if information was missing from TMA slides. IR expression (cytoplasmic and membranous) was quantified using Definiens image analysis software (Tissue Studio, Definiens AG, Munich, Germany). We calculated an IR H-score as a weighted sum of the intensity of IHC cytoplasmic and membranous expression as follows: H-score = % of positively stained cells at weak intensity category X 1 + % of positively stained cells at median intensity category X 2 + % of positively stained cells at high intensity category X 3 [35]. In a subset of the cases (N=124), we assessed the correlation of IR expression between manual reading by expert pathologist and the image analysis, and observed a sensitivity and specificity of 83% and 69%, respectively for the image analysis if considering the manual reading as the gold standard. The median of the H-score was chosen as the cut-off to determine IR positivity: positive if H-score >the median value. Because there has not been an established standard cutoff point for determining IR expression status, we performed sensitivity analyses using different cutoff points (i.e. >33% vs. 33%, or >75% vs. 75%) for the IR H-score. 540 tumors with missing information on any of the four tumor markers and an additional small subset of ER-/PR+ tumors (n=47) were excluded from the analysis.

Statistical Analysis

For this analysis, follow-up time accrued from 1980 when alcohol consumption was first assessed until the diagnosis of any type of cancers, death or June, 2006. Only invasive breast cancer cases were included in the analysis; non-invasive cases or invasive cases not included in TMA were censored. A constrained Cox competing-risk survival model [36] which allows for assessment of heterogeneity of alcohol and breast cancer association according to specific tumor marker while accounting for other markers was used to estimate hazard ratio (HR) and 95% confidence interval (CI). We used this model because stratification of data according to multiple marker subtypes becomes impractical given small number of cases in some strata and some of the markers are highly correlated (e.g., ER and AR). Wald tests were used to assess if the association differed by tumor marker expression (i.e. positive vs. negative). Covariates included in the model were common breast cancer risk factors and possible confounders (details in footnotes of Table 3). We first evaluated the alcohol and breast cancer association by considering each tumor marker separately and then assessed the association for each marker while accounting for other tumor markers. For instance, when evaluating the association according to AR expression, we first fit the model according to AR subtypes without considering other tumor markers; we then estimated adjusted hazard

ratios taking into account other tumor markers (i.e. ER, PR and IR), controlling for heterogeneity of the alcohol and breast cancer association according to these tumor markers. Tests for trend were performed by modeling the median values of alcohol intake categories as a continuous variable in the multivariable models.

We also assessed the joint expression of AR, ER and PR by stratifying data according to specific marker subtypes in standard Cox proportional hazards model [37]. IR was not included in this analysis because no evidence of significant heterogeneity of the alcohol and breast cancer association according to IR subtypes was found, and in a preliminary analysis, similarly no heterogeneity was observed by further including IR with AR, ER and PR classifications and case numbers were small in many of these 4-receptor subtype categories. Likelihood ratio tests were used to assess global heterogeneity and pairwise difference between subgroups. We further classified subtypes according to the number of positive tumor markers, defined as an ordinal number (i.e. 0, 1, 2, 3) and performed a trend test to assess if the alcohol and breast cancer risk increases as the number of positive tumor markers increase. All analyses were performed using SAS version 9.3 with a 2-sided significance P value of < 0.05 .

Results

Table 1 presents the characteristics of the study population according to cumulative average alcohol consumption in 1992, the midpoint of the follow-up time. Most characteristics were approximately evenly distributed across the groups except that increasing levels of alcohol consumption were correlated with lower current BMI and women who consumed higher alcohol were more likely to be current smokers. Among post-menopausal women, non-drinkers were less likely to be MHT users compared to alcohol consumers, although among alcohol drinkers, there was no clear linear trend for MHT use across increasing levels of alcohol intake.

A total of 1,975 tumors (77%) were AR+, 2,054 (80%) were ER+, 1,754 (69%) were PR+ and 1,277 (50%) were IR+, respectively (Table 2). AR expression was highly correlated with ER and PR expression: compared to ER– tumors, ER+ tumors were approximately 8.7 times (95%CI = 7.0, 10.8) more likely to be AR+; compared to PR– tumors, PR+ tumors were also more likely to be AR+ (OR = 4.9, 95%CI = 4.1, 6.0). However, AR expression was moderately correlated with IR expression: IR+ tumors were about 1.8 (95%CI = 1.4, 2.1) times more likely to be AR+, compared to IR– tumors.

Because only cases who had information on all four tumor markers contributed to the analysis, we first evaluated alcohol consumption and risk of breast cancer among these cases to compare results with those from a larger analysis of all cases diagnosed 1980~2008 [2], and found that the association was similar in our study population as in the larger data set. We found that consumption of at least 30 g alcohol per day (vs. no alcohol consumption) was associated with an increased risk of breast cancer (RR = 1.41, 95%CI = 1.16, 1.72), which is consistent and similar to results in our earlier report (RR = 1.51, 95%CI = 1.35, 1.70), although no significantly increased risk was observed among low to moderate alcohol consumers in the current study population (data not shown). A similar dose-response

relationship also was observed (RR per 11 g/d: 1.09; 95%CI = 1.04, 1.13) compared to that in the earlier study (RR per 10g/d: 1.10; 95%CI = 1.07, 1.12)

When considering each tumor marker separately, we did not find any significant heterogeneity of the alcohol and breast cancer association by hormone receptor status ($P_{\text{heterogeneity}}$ range 0.06–0.99; Table 3). However, increasing alcohol consumption appeared similarly positively associated with risk of AR+, ER+, or PR+ breast cancer but not AR–, ER–, or PR– breast cancer. For example, each increment of 11g alcohol (approximately 1 drink) per day was associated with a 10% increased risk (HR = 1.10, 95%CI = 1.05, 1.16) of AR+ breast cancer while there was no apparent dose-response relationship among AR– breast cancer (HR = 1.02, 95%CI = 0.93, 1.13). Comparable results were observed for ER and PR. Similarly, an increased risk, of approximately 50%, was seen among women who consumed at least 30 g of alcohol daily (vs. non-drinkers) for AR+, ER+ and PR+ breast cancer respectively but not for AR–, ER– or PR– breast cancer. The significantly increased risk was observed only among the highest alcohol category (i.e. 30+ g/d) but not in low to moderate alcohol categories (e.g. 20 – <30 g/d) in AR+, ER+ and PR+ tumors, respectively, although a statistically significant linear trend was observed. In contrast, hazard ratios were very similar comparing IR+ with IR– breast tumors ($P_{\text{heterogeneity}}$ = 0.99 and 0.70, when alcohol assessed as categorical or per 11g/d, respectively). Each additional drink daily was significantly associated with about 8% (95%CI = 1%, 15%) and 10% (95%CI = 3%, 16%) increased risk of IR+ and IR– breast cancer, respectively. Sensitivity analyses using different cutoff points for the IR H-score found that results were essentially unchanged when IR positivity was defined as either >33% (vs. 33%) or >75% (vs. 75%) (data not shown).

When considering the four tumor makers simultaneously, there again was no significant heterogeneity for any of the four markers, although some suggestive differences were seen (Table 4). Compared to results when each tumor marker was considered separately (Table 3), hazard ratios from the adjusted models remained similar among AR+, ER+ or PR+ breast cancer. However, associations for AR–, ER– or PR– tumors became more similar to the hormone receptor positive associations, although these changes varied somewhat by receptor. Alcohol associations for AR– became more similar to AR+, particularly in the categorical model. Compared to women who never consumed alcohol, women who consumed 30+ g/d alcohol had a 44% increased risk of AR+ breast cancer (95%CI = 1.15, 1.81) and a non-significant 31% increased risk for AR– breast cancer (95%CI = 0.84, 2.05). For ER, compared to Table 3 findings, hazard ratios after accounting for the other markers, were largely unchanged. For example, consumers of 30+ g/d of alcohol (compared to non-users) had a 51% higher risk of ER+ tumors (95% CI = 1.19, 1.90), but an 8% increased risk of ER– tumors (95% CI = 0.56, 2.09). Similar to results in Table 3, among AR+ or ER+ breast tumors, a significantly increased risk was seen only in the 30+ g/d alcohol category, although a significant dose-response relationship also was observed. For IR and PR, the hazard ratios associated with alcohol intake among hormone receptor positive tumors looked very similar to those for hormone receptor negative tumors ($P_{\text{heterogeneity}}$ range 0.52 ~ 0.74).

The assessment of joint expression of AR, ER and PR showed that increased risk was observed among tumors expressing all three markers (HR for per drink daily: 1.11; 95%CI = 1.06, 1.17) but not among the AR–/ER–/PR– subgroup (HR = 0.99; 95%CI = 0.88, 1.12)

(Table 5). Despite no significant overall heterogeneity across all subgroups ($P_{\text{heterogeneity}} = 0.22$), the pair-wise comparison between AR+/ER+/PR+ and AR-/ER-/PR- was significant ($P_{\text{heterogeneity}} = 0.03$). When classifying subtypes according to number of positive tumor markers, we observed that increasing number of positive markers was associated with increased hazard ratios ($P_{\text{trend}} = 0.03$). For instance, no association was observed among tumors negative for AR, ER and PR (HR per drink daily: 0.96; 95%CI = 0.83, 1.10), while modestly increased risk was found among tumors expressing at least two (HR = 1.11, 95%CI = 1.01, 1.22) or three (HR = 1.12, 95%CI = 1.06, 1.18) of the hormone markers.

Discussion

We evaluated adult alcohol consumption and risk of breast cancer according to tumor hormone receptors in a large prospective study over a twenty-six year period. After taking into account possible heterogeneity of the alcohol and breast cancer association by other tumor markers (i.e. AR, PR and IR), increasing alcohol consumption was positively associated with risk of ER+ or AR+ breast cancer, but not ER- or AR- breast cancer, although this difference was not statistically significant. However, the alcohol and breast cancer association appeared independent of IR and PR expression. Finally, when assessing the joint expression of tumor hormone receptors, the association was more pronounced among strongly hormone positive tumors (i.e. AR+/ER+/PR+).

To our knowledge, our study provides the first evaluation of the association between alcohol and breast cancer risk by tumor AR and IR expression. However, both receptors have been evaluated in relation to breast cancer prognosis. AR has been consistently associated with better prognosis [14], primarily among ER positive tumors [14], while data for IR are more limited and inconsistent [38,39]. Although the alcohol and breast cancer association did not significantly vary by tumor IR expression in our study, insulin and IR has gained more interest as increasing experimental and pre-clinical data have supported the possible role of IR in breast cancer etiology [21]. Interestingly, as we mentioned earlier, alcohol consumption can improve insulin sensitivity and is inversely correlated with circulating insulin levels, which is contrary to the positive correlation seen between alcohol intake and circulating steroids hormones, such as estrogens and androgens. Further epidemiologic studies evaluating the potential influence of these two receptors in mediating lifestyle and breast cancer associations would be useful. Furthermore, we assessed IR expression, for the first time, using computer assisted digital image analysis (i.e. Definiens) instead of manual reading by a pathologist. While the digital analysis saves substantial time and cost, no study has evaluated the consistency between the two methods, particularly for IR. We observed a sensitivity and specificity of 83% and 69%, respectively for the image analysis if considering the manual reading as the gold standard in a subset of the cases. However, this requires confirmation in future studies that apply the digital analysis.

Whether the association of alcohol intake and breast cancer risk varies by ER and PR status of the tumor has been assessed in a number of studies. A meta-analysis of 4 prospective cohort and 16 case-control studies reported that per 10 g/d alcohol was associated with 12% (95%CI = 8%, 15%) increased risk of all ER+ breast cancer but not ER-/PR- breast cancer (HR = 1.04, 95%CI = 0.98, 1.09), with significant heterogeneity between all ER+ and ER

–/PR– [4]. In two subsequent cohort studies, for each increment of 1 drink/day, a slightly but significantly increased (5–8%) risk was observed for ER+/PR+ breast cancer while neither study found an association for ER–/PR– breast cancer [5,6]. Our earlier study of 7,690 cases diagnosed 1980–2008 in the NHS also observed positive associations among ER+/PR+ and ER+/PR– breast cancer but not among ER–/PR– tumors, although this difference was not statistically significant [2]. However, two recent prospective studies found that the alcohol and breast cancer association appeared independent of ER and PR status [3,40]. Consistent with most of the previous studies, we found that the alcohol and breast cancer association varied suggestively by ER status when ER was considered individually or simultaneously with other tumor markers, although the differences were not statistically significant.

Although the alcohol and breast cancer association did not vary significantly by AR expression status individually, when evaluating joint expression of AR, ER and PR, a significantly increased risk was observed in tumors expressing all three markers (i.e. AR+/ER+/PR+) while no association was seen in the AR–/ER–/PR– subgroup, with significant difference between these two categories. Thus, it appears that androgen signaling, in addition to estrogen signaling, may be involved in the alcohol and breast cancer association and may biologically interact with estrogens. Supporting data are the observations that no significant heterogeneity was found for any of the three hormone receptors when they were mutually adjusted, while the joint estrogen and androgen signaling showed significant increased risk (vs. AR–/ER–/PR– tumors). Taken together, our data suggest that the alcohol and breast cancer association may be more pronounced among sex steroid hormone-sensitive tumor subgroup(s) although additional large studies are needed to confirm this finding.

A major strength of this study was the assessment of alcohol consumption and risk of breast cancer by several breast tumor markers, of which AR and IR were evaluated for the first time. Other strengths included prospective measurement of alcohol consumption with updated exposure information, a large number of invasive breast cancer cases, and use of a constrained competing-risk survival model which allows the assessment of heterogeneity of the association while taking into account the other tumor markers. Our study also has several limitations. The cases contributing to this analysis was a subset of all eligible cases in the cohort; however, cases from whom tumor marker information were not available were not significantly different from cases included in this analysis in terms of characteristics and accepted breast cancer risk factors (Supplementary Table 2). Another limitation is that since no standard method has been established for determining IR positivity, we chose to use the IR H-score and consider the median of the H-score as the cutoff point to determine IR positivity. However, sensitivity analysis showed that the association did not vary by different cutoff points of the H-score (e.g. 33% or 75%). Additionally, we observed only moderate sensitivity and specificity when comparing manual pathologist assessment vs. image-analysis results for IR, suggesting some potential misclassification in our IR definition that could decrease our ability to detect different associations by IR status.

To summarize, we did not find that the alcohol and breast cancer association significantly varied according to each of the four tumor markers assessed (i.e. AR, ER, PR and IR), after

considering these tumor markers simultaneously. However, assessment of joint effect of androgen and estrogen signaling suggests a possible biological interaction between these two pathways. Our data also did not support an important role for IR and PR in the alcohol and breast cancer association. These findings highlight the importance of incorporating breast cancer subtypes in determining risk factor associations. Further studies are warranted to confirm these findings and may extend to other relevant markers in order to better understand the underlying mechanism of the effect of alcohol consumption on breast cancer risk.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This study was supported by research grants CA166666, CA186107 and CA87969 from the National Institutes of Health and SAC 110014 from the Komen Foundation. We would like to thank the participants and staff of the Nurses' Health Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data.

References

1. Allen NE, Beral V, Casabonne D, Kan SW, Reeves GK, Brown A, Green J. Moderate alcohol intake and cancer incidence in women. *Journal of the National Cancer Institute*. 2009; 101(5):296–305. [PubMed: 19244173]
2. Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. *JAMA*. 2011; 306(17):1884–1890. [PubMed: 22045766]
3. Park SY, Kolonel LN, Lim U, White KK, Henderson BE, Wilkens LR. Alcohol consumption and breast cancer risk among women from five ethnic groups with light to moderate intakes: the Multiethnic Cohort Study. *International Journal of Cancer*. 2014; 134(6):1504–1510.
4. Suzuki R, Orsini N, Mignone L, Saji S, Wolk A. Alcohol intake and risk of breast cancer defined by estrogen and progesterone receptor status—a meta-analysis of epidemiological studies. *International Journal of Cancer*. 2008; 122(8):1832–1841.
5. Lew JQ, Freedman ND, Leitzmann MF, Brinton LA, Hoover RN, Hollenbeck AR, Schatzkin A, Park Y. Alcohol and risk of breast cancer by histologic type and hormone receptor status in postmenopausal women: the NIH-AARP Diet and Health Study. *American Journal of Epidemiology*. 2009; 170(3):308–317. [PubMed: 19541857]
6. Li CI, Chlebowski RT, Freiberg M, Johnson KC, Kuller L, Lane D, Lessin L, O'Sullivan MJ, Wactawski-Wende J, Yasmeeen S, Prentice R. Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study. *Journal of the National Cancer Institute*. 2010; 102(18):1422–1431. [PubMed: 20733117]
7. Reichman ME, Judd JT, Longcope C, Schatzkin A, Clevidence BA, Nair PP, Campbell WS, Taylor PR. Effects of alcohol consumption on plasma and urinary hormone concentrations in premenopausal women. *Journal of the National Cancer Institute*. 1993; 85(9):722–727. [PubMed: 8478958]
8. Dorgan JF, Baer DJ, Albert PS, Judd JT, Brown ED, Corle DK, Campbell WS, Hartman TJ, Tejpar AA, Clevidence BA, Giffen CA, Chandler DW, Stanczyk FZ, Taylor PR. Serum hormones and the alcohol-breast cancer association in postmenopausal women. *Journal of the National Cancer Institute*. 2001; 93(9):710–715. [PubMed: 11333294]

9. Onland-Moret NC, Peeters PH, van der Schouw YT, Grobbee DE, van Gils CH. Alcohol and endogenous sex steroid levels in postmenopausal women: a cross-sectional study. *The Journal of Clinical Endocrinology and Metabolism*. 2005; 90(3):1414–1419. [PubMed: 15572431]
10. Rinaldi S, Peeters PH, Bezemer ID, Dossus L, Biessy C, Sacerdote C, Berrino F, Panico S, Palli D, Tumino R, Khaw KT, Bingham S, Allen NE, Key T, Jensen MK, Overvad K, Olsen A, Tjønneland A, Amiano P, Ardanaz E, Agudo A, Martinez-Garcia C, Quiros JR, Tormo MJ, Nagel G, Linseisen J, Boeing H, Schulz M, Grobbee DE, Bueno-de-Mesquita HB, Koliva M, Kyriazi G, Trichopoulou A, Boutron-Ruault MC, Clavel-Chapelon F, Ferrari P, Slimani N, Saracci R, Riboli E, Kaaks R. Relationship of alcohol intake and sex steroid concentrations in blood in pre- and post-menopausal women: the European Prospective Investigation into Cancer and Nutrition. *Cancer Causes Control*. 2006; 17(8):1033–1043. [PubMed: 16933054]
11. Key TJ, Appleby PN, Reeves GK, Roddam AW, Helzlsouer KJ, Alberg AJ, Rollison DE, Dorgan JF, Brinton LA, Overvad K, Kaaks R, Trichopoulou A, Clavel-Chapelon F, Panico S, Duell EJ, Peeters PH, Rinaldi S, Fentiman IS, Dowsett M, Manjer J, Lenner P, Hallmans G, Baglietto L, English DR, Giles GG, Hopper JL, Severi G, Morris HA, Hankinson SE, Tworoger SS, Koenig K, Zeleniuch-Jacquotte A, Arslan AA, Toniolo P, Shore RE, Krogh V, Micheli A, Berrino F, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Lui LY, Cummings SR, Gunter MJ, Rohan TE, Strickler HD. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. *British Journal of Cancer*. 2011; 105(5):709–722. [PubMed: 21772329]
12. Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW, Lee KS. Expression of androgen receptors in primary breast cancer. *Ann Oncol*. 2010; 21(3):488–492. [PubMed: 19887463]
13. Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, Marotti JD, Hankinson SE, Colditz GA, Tamimi RM. Androgen receptor expression and breast cancer survival in postmenopausal women. *Clin Cancer Res*. 2011; 17(7):1867–1874. [PubMed: 21325075]
14. Campagnoli C, Pasanisi P, Castellano I, Abba C, Brucato T, Berrino F. Postmenopausal breast cancer, androgens, and aromatase inhibitors. *Breast Cancer Research and Treatment*. 2013; 139(1):1–11. [PubMed: 23572296]
15. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. *Journal of the National Cancer Institute*. 2002; 94(8):606–616. [PubMed: 11959894]
16. Zhang X, Tworoger SS, Eliassen AH, Hankinson SE. Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. *Breast Cancer Research and Treatment*. 2013; 137(3):883–892. [PubMed: 23283524]
17. Key TJ, Appleby PN, Reeves GK, Travis RC, Alberg AJ, Barricarte A, Berrino F, Krogh V, Sieri S, Brinton LA, Dorgan JF, Dossus L, Dowsett M, Eliassen AH, Fortner RT, Hankinson SE, Helzlsouer KJ, Hoff man-Bolton J, Comstock GW, Kaaks R, Kahle LL, Muti P, Overvad K, Peeters PH, Riboli E, Rinaldi S, Rollison DE, Stanczyk FZ, Trichopoulos D, Tworoger SS, Vineis P. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. *The Lancet*. 2013; 14(10):1009–1019. [PubMed: 23890780]
18. Dorgan JF, Reichman ME, Judd JT, Brown C, Longcope C, Schatzkin A, Campbell WS, Franz C, Kahle L, Taylor PR. The relation of reported alcohol ingestion to plasma levels of estrogens and androgens in premenopausal women (Maryland, United States). *Cancer Causes Control*. 1994; 5(1):53–60. [PubMed: 8123779]
19. Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frittitta L, Vannelli GB, Brand R, Goldfine ID, Vigneri R. Elevated insulin receptor content in human breast cancer. *The Journal of Clinical Investigation*. 1990; 86(5):1503–1510. [PubMed: 2243127]
20. Papa V, Costantino A, Belfiore A. Insulin receptor what role in breast cancer? *Trends in Endocrinology and Metabolism: TEM*. 1997; 8(8):306–312. [PubMed: 18406819]
21. Belfiore A, Malaguarnera R. Insulin receptor and cancer. *Endocrine-related cancer*. 2011; 18(4):R125–147. [PubMed: 21606157]
22. Lazarus R, Sparrow D, Weiss ST. Alcohol intake and insulin levels. *The Normative Aging Study. American Journal of Epidemiology*. 1997; 145(10):909–916. [PubMed: 9149662]

23. Kiechl S, Willeit J, Poewe W, Egger G, Oberhollenzer F, Muggeo M, Bonora E. Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study). *BMJ (Clinical research ed)*. 1996; 313(7064):1040–1044.
24. Davies MJ, Baer DJ, Judd JT, Brown ED, Campbell WS, Taylor PR. Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial. *JAMA*. 2002; 287(19):2559–2562. [PubMed: 12020337]
25. Ahern TP, Hankinson SE, Willett WC, Pollak MN, Eliassen AH, Tamimi RM. Plasma C-peptide, mammographic breast density, and risk of invasive breast cancer. *Cancer Epidemiol Biomarkers Prev*. 2013; 22(10):1786–1796. [PubMed: 24097198]
26. Gaudet MM, Patel AV, Teras LR, Sun J, Campbell PT, Stevens VL, Jacobs EJ, Gapstur SM. Obesity-related markers and breast cancer in CPS-II Nutrition Cohort. *International Journal of Molecular Epidemiology and Genetics*. 2013; 4(3):156–166. [PubMed: 24046808]
27. Autier P, Koechlin A, Boniol M, Mullie P, Bolli G, Rosenstock J, Boyle P. Serum insulin and C-peptide concentration and breast cancer: a meta-analysis. *Cancer Causes Control*. 2013; 24(5): 873–883. [PubMed: 23408243]
28. Tamimi RM, Colditz GA, Hazra A, Baer HJ, Hankinson SE, Rosner B, Marotti J, Connolly JL, Schnitt SJ, Collins LC. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. *Breast Cancer Research and Treatment*. 2012; 131(1):159–167. [PubMed: 21830014]
29. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R, Spurdle AB, Blows F, Driver K, Flesch-Janys D, Heinz J, Sinn P, Vrieling A, Heikkinen T, Aittomäki K, Heikkilä P, Blomqvist C, Lissowska J, Peplonska B, Chanock S, Figueroa J, Brinton L, Hall P, Czene K, Humphreys K, Darabi H, Liu J, Van 't Veer LJ, van Leeuwen FE, Andrulis IL, Glendon G, Knight JA, Mulligan AM, O'Malley FP, Weerasooriya N, John EM, Beckmann MW, Hartmann A, Weibrecht SB, Wachter DL, Jud SM, Loehberg CR, Baglietto L, English DR, Giles GG, McLean CA, Severi G, Lambrechts D, Vandrope T, Weltens C, Paridaens R, Smeets A, Neven P, Wildiers H, Wang X, Olson JE, Cafourek V, Fredericksen Z, Kosel M, Vachon C, Cramp HE, Connley D, Cross SS, Balasubramanian SP, Reed MW, Dork T, Bremer M, Meyer A, Karstens JH, Ay A, Park-Simon TW, Hillemanns P, Arias Perez JJ, Menendez Rodriguez P, Zamora P, Benitez J, Ko YD, Fischer HP, Hamann U, Pesch B, Bruning T, Justenhoven C, Brauch H, Eccles DM, Tapper WJ, Gerty SM, Sawyer EJ, Tomlinson IP, Jones A, Kerin M, Miller N, McInerney N, Anton-Culver H, Ziogas A, Shen CY, Hsiung CN, Wu PE, Yang SL, Yu JC, Chen ST, Hsu GC, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Lindblom A, Margolin S, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Gorski B, Gronwald J, Hooning MJ, Hollestelle A, van den Ouweland AM, Jager A, Kriege M, Tilanus-Linthorst MM, Collee M, Wang-Gohrke S, Pylkas K, Jukkola-Vuorinen A, Mononen K, Grip M, Hirvikoski P, Winqvist R, Mannermaa A, Kosma VM, Kauppinen J, Kataja V, Auvinen P, Soini Y, Sironen R, Bojesen SE, Orsted DD, Kaur-Knudsen D, Flyger H, Nordestgaard BG, Holland H, Chenevix-Trench G, Manoukian S, Barile M, Radice P, Hankinson SE, Hunter DJ, Tamimi R, Sangrajrang S, Brennan P, McKay J, Odefrey F, Gaborieau V, Devilee P, Huijts PE, Tollenaar RA, Seynaeve C, Dite GS, Apicella C, Hopper JL, Hammet F, Tsimiklis H, Smith LD, Southey MC, Humphreys MK, Easton D, Pharoah P, Sherman ME, Garcia-Closas M. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. *Journal of the National Cancer Institute*. 2011; 103(3):250–263. [PubMed: 21191117]
30. Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, Longcope C, Speizer FE. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. *Journal of the National Cancer Institute*. 1995; 87(17):1297–1302. [PubMed: 7658481]
31. Giovannucci E, Colditz G, Stampfer MJ, Rimm EB, Litin L, Sampson L, Willett WC. The assessment of alcohol consumption by a simple self-administered questionnaire. *American Journal of Epidemiology*. 1991; 133(8):810–817. [PubMed: 2021148]
32. Stampfer MJ, Willett WC, Speizer FE, Dysert DC, Lipnick R, Rosner B, Hennekens CH. Test of the National Death Index. *American Journal of Epidemiology*. 1984; 119(5):837–839. [PubMed: 6720679]

33. Rich-Edwards JW, Corsano KA, Stampfer MJ. Test of the National Death Index and Equifax Nationwide Death Search. *American Journal of Epidemiology*. 1994; 140(11):1016–1019. [PubMed: 7985649]
34. Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. *Breast Cancer Res*. 2008; 10(4):R67. [PubMed: 18681955]
35. Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarty KS Jr. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. *Cancer Research*. 1989; 49(4):1052–1056. [PubMed: 2643460]
36. Rosner B, Glynn RJ, Tamimi RM, Chen WY, Colditz GA, Willett WC, Hankinson SE. Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers. *American Journal of Epidemiology*. 2013; 178(2):296–308. [PubMed: 23645624]
37. Lunan M, McNeil D. Applying Cox regression to competing risks. *Biometrics*. 1995; 51(2):524–532. [PubMed: 7662841]
38. Mulligan AM, O'Malley FP, Ennis M, Fantus IG, Goodwin PJ. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. *Breast Cancer Research and Treatment*. 2007; 106(1):39–47. [PubMed: 17221153]
39. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE. Phosphorylated insulin-like growth factor/insulin receptor is present in all breast cancer subtypes and is related to poor survival. *Cancer Research*. 2008; 68(24):10238–10246. [PubMed: 19074892]
40. Romieu I, Scoccianti C, Chajes V, de Batlle J, Biessy C, Dossus L, Baglietto L, Clavel-Chapelon F, Overvad K, Olsen A, Tjønneland A, Kaaks R, Lukanova A, Boeing H, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Sieri S, Tumino R, Vineis P, Panico S, Bueno-de-Mesquita HB, Gils CH, Peeters P, Lund E, Skeie G, Weiderpass E, Quiros JR, Chirlaque MD, Ardanaz E, Sanchez MJ, Duell EJ, Amiano P, Borgquist S, Wirfalt E, Hallmans G, Johansson I, Nilsson LM, Khaw KT, Wareham N, Key TJ, Travis RC, Murphy N, Wark PA, Ferrari P, Riboli E. Alcohol intake and breast cancer in the European Prospective investigation into Cancer and Nutrition: Short title: Alcohol intake and breast cancer: Alcohol intake and breast cancer. *International Journal of Cancer*. 2015; 137(8):1921–30.

Table 1

Characteristics of Study Population in 1992^a

	Cumulative Average Daily Alcohol Intake, g/d						
	0	>0 – <5	5 – <10	10 – <20	20 – <30	30	
All women, No.	21310	37897	12076	11039	3961	3227	
Age, y	59.1(7.2)	58.1(7.2)	58.3(7.1)	58.9(7.0)	59.3(6.9)	59.92(6.7)	
Age at menarche, y	12.4(1.8)	12.4(1.8)	12.5(1.8)	12.5(1.8)	12.5(1.7)	12.49(1.8)	
Nulliparous, %	5	5	6	7	7	8	
Parity ^b	2.8(0.7)	2.8(0.7)	2.8(0.7)	2.8(0.7)	2.8(0.7)	2.8(0.7)	
Age at first birth, y	25.2(3.4)	25.1(3.3)	25.1(3.3)	25.1(3.3)	25.0(3.2)	25.1(3.3)	
BMI at 18 yrs, kg/m ²	21.7(3.3)	21.5(3.0)	21.1(2.6)	21.1(2.7)	21.0(2.5)	21.13(2.8)	
BMI, kg/m ²	27.3(5.7)	26.6(5.2)	25.4(4.4)	24.9(4.1)	24.8(4.0)	24.84(4.2)	
Age at menopause ^c , y	48.9(4.7)	49.0(4.7)	49.1(4.8)	49.1(4.4)	49.1(4.3)	49.04(4.0)	
Premenopausal, %	15	16	16	15	15	14	
Current MHT use, %	33	38	41	41	42	35	
Current smoker, %	11	14	15	20	22	34	
Family history of breast cancer in a first degree relative, %	11	12	12	13	12	12	
History of benign breast disease, %	41	43	45	44	44	40	

^a All variables except age are age standardized.^b Among parous women^c Among women with natural menopause or bilateral oophorectomy

Table 2
Joint distribution of AR, ER, PR and IR expression among invasive breast cancer cases (N=2552), Nurses' Health Study 1980 – 2006.

AR	ER	PR	IR	No. of Cases	%
+	+	+	+	854	33.5
+	+	+	-	667	26.1
-	-	-	-	181	7.1
-	+	+	-	135	5.3
+	-	-	-	133	5.2
+	+	-	-	125	4.9
+	+	-	+	122	4.8
-	-	-	+	110	4.3
-	+	+	+	98	3.8
+	-	-	+	74	2.9
-	+	-	-	34	1.3
-	+	-	+	19	0.7

Alcohol Consumption and Breast Cancer Risk According to AR, ER, PR and IR subtypes, Nurses' Health Study 1980 – 2006.

Table 3

Cumulative average daily intake (g/day)								
0	>0 – <5	5 – <10	10 – <20	20 – <30	30	P-trend	Per 11g/d	
AR - positive								
Cases, No.	442	792	266	285	86	104		
HR (95%CI) ^a	1.00 ^{Ref}	1.05 (0.93, 1.18)	1.09 (0.93, 1.27)	1.17 (1.00, 1.36)	1.05 (0.83, 1.33)	1.50 (1.20, 1.86)	0.001	
AR - negative								
Cases, No.	155	236	70	70	20	26		
HR (95%CI) ^a	1.00 ^{Ref}	0.89 (0.73, 1.10)	0.84 (0.63, 1.12)	0.87 (0.65, 1.17)	0.75 (0.47, 1.21)	1.19 (0.78, 1.82)	0.94	
<i>P</i> -het ^b : 0.16 and <i>P</i> -het ^c : 0.17								
ER - positive								
Cases, No.	470	817	272	298	86	111		
HR (95%CI) ^a	1.00 ^{Ref}	1.01 (0.90, 1.13)	1.04 (0.90, 1.21)	1.15 (0.99, 1.33)	0.99 (0.79, 1.25)	1.53 (1.24, 1.89)	0.0004	
ER - negative								
Cases, No.	127	211	64	57	20	19		
HR (95%CI) ^a	1.00 ^{Ref}	1.01 (0.81, 1.26)	0.97 (0.71, 1.32)	0.87 (0.63, 1.20)	0.93 (0.57, 1.49)	1.01 (0.62, 1.65)	0.62	
<i>P</i> -het ^b : 0.06 and <i>P</i> -het ^c : 0.15								
PR - positive								
Cases, No.	399	695	239	254	74	93		
HR (95%CI) ^a	1.00 ^{Ref}	1.00 (0.89, 1.14)	1.08 (0.92, 1.27)	1.16 (0.99, 1.37)	1.02 (0.79, 1.31)	1.54 (1.22, 1.94)	0.0005	
PR - negative								
Cases, No.	198	333	97	101	32	37		
HR (95%CI) ^a	1.00 ^{Ref}	1.02 (0.85, 1.22)	0.92 (0.72, 1.18)	0.95 (0.74, 1.22)	0.90 (0.62, 1.32)	1.19 (0.83, 1.70)	0.86	
<i>P</i> -het ^b : 0.08 and <i>P</i> -het ^c : 0.20								
IR - positive								
Cases, No.	301	520	163	178	51	64		
HR (95%CI) ^a	1.00 ^{Ref}	1.00 (0.86, 1.15)	0.98 (0.81, 1.20)	1.10 (0.91, 1.33)	0.94 (0.69, 1.27)	1.43 (1.09, 1.89)	0.04	
IR - negative								

Cumulative average daily intake (g/day)						
	0	>0 – <5	5 – <10	10 – <20	20 – <30	30
Cases, No.	296	508	173	177	55	66
HR (95%CI) ^a	1.00 ^{Ref}	1.02 (0.88, 1.18)	1.07 (0.88, 1.30)	1.09 (0.90, 1.32)	1.02 (0.76, 1.36)	1.41 (1.07, 1.85)
P-het^b: 0.99 and P-het^c: 0.70						
						Per 11g/d
						1.10 (1.03, 1.16)
						0.03
						P-trend

^a Adjusted for first degree family history of breast cancer, history of benign breast disease, age (continuous), age at menarche (<12, 12, 13, 13+, missing), age at first birth and no. of children (nulliparous, 1–2 children and <25 yrs, 1–2 children and 25–29 yrs, 1–2 children and 30 yrs, 3–4 children and <25 yrs, 3–4 children and 25–29 yrs, 3–4 children and <25 yrs, >4 children and 25 yrs, missing category), BMI (<23, 23–<25, 25–<27.5, 27.5–<30, 30–<35, 35+, missing, kg/2), smoking (never, former, current, missing), menopausal hormone therapy use (never, past user, current <5 yrs, current 5+ yrs, premenopausal, missing), age at menopause (continuous) and missing indicator for age at menopause.

^b P-value for heterogeneity test of marker expression positive vs. negative when alcohol evaluated as a categorical variable

^c P-value for heterogeneity test of marker expression positive vs. negative when alcohol evaluated continuously as 11g/day.

Alcohol Consumption and Breast Cancer Risk According to AR, ER, PR and IR Subtypes After Accounting for Other Markers, Nurses' Health Study 1980 – 2006.

Table 4

Cumulative average daily intake (g/day)									
	0	>0 – <5	5 – <10	10 – <20	20 – <30	30	P-trend	Per 11g/d	
AR - positive									
Cases, No.	442	792	266	285	86	104			
HR (95%CI) ^a	1.00 ^{Ref}	1.06 (0.94, 1.19)	1.10 (0.94, 1.29)	1.15 (0.98, 1.35)	1.07 (0.84, 1.35)	1.44 (1.15, 1.81)	0.004		1.10 (1.04, 1.15)
AR - negative									
Cases, No.	155	236	70	70	20	26			
HR (95%CI) ^a	1.00 ^{Ref}	0.87 (0.69, 1.09)	0.83 (0.61, 1.13)	0.91 (0.67, 1.25)	0.73 (0.44, 1.21)	1.31 (0.84, 2.05)	0.56		1.04 (0.94, 1.15)
<i>P</i> -het ^b : 0.49 and <i>P</i> -het ^c : 0.37									
ER - positive									
Cases, No.	470	817	272	298	86	111			
HR (95%CI) ^a	1.00 ^{Ref}	1.00 (0.88, 1.13)	0.98 (0.82, 1.17)	1.12 (0.94, 1.32)	0.94 (0.72, 1.22)	1.51 (1.19, 1.90)	0.005		1.09 (1.04, 1.15)
ER - negative									
Cases, No.	127	211	64	57	20	19			
HR (95%CI) ^a	1.00 ^{Ref}	1.05 (0.76, 1.46)	1.25 (0.80, 1.97)	0.99 (0.63, 1.55)	1.15 (0.58, 2.28)	1.08 (0.56, 2.09)	0.91		1.04 (0.91, 1.20)
<i>P</i> -het ^b : 0.42 and <i>P</i> -het ^c : 0.58									
PR - positive									
Cases, No.	399	695	239	254	74	93			
HR (95%CI) ^a	1.00 ^{Ref}	1.00 (0.86, 1.15)	1.11 (0.91, 1.35)	1.11 (0.92, 1.35)	1.02 (0.76, 1.38)	1.43 (1.09, 1.88)	0.02		1.09 (1.03, 1.16)
PR - negative									
Cases, No.	198	333	97	101	32	37			
HR (95%CI) ^a	1.00 ^{Ref}	1.04 (0.81, 1.32)	0.87 (0.62, 1.22)	1.04 (0.76, 1.43)	0.88 (0.53, 1.46)	1.36 (0.88, 2.11)	0.45		1.07 (0.97, 1.18)
<i>P</i> -het ^b : 0.61 and <i>P</i> -het ^c : 0.73									
IR - positive									
Cases, No.	301	520	163	178	51	64			
HR (95%CI) ^a	1.00 ^{Ref}	0.99 (0.86, 1.15)	0.97 (0.80, 1.18)	1.07 (0.88, 1.30)	0.92 (0.68, 1.25)	1.39 (1.05, 1.84)	0.08		1.07 (1.00, 1.14)

Cumulative average daily intake (g/day)						
	0	>0 – <5	5 – <10	10 – <20	20 – <30	30
IR - negative						
Cases, No.	296	508	173	177	55	66
HR (95%CI) ^a	1.00 ^{Ref}	1.02 (0.88, 1.19)	1.09 (0.90, 1.32)	1.11 (0.91, 1.34)	1.03 (0.77, 1.39)	1.43 (1.09, 1.88)
P-het^b: 0.74 and P-het^c: 0.52						
						1.10 (1.04, 1.16)
						0.02

^a Adjusted for the same covariates as in footnote a in Table 3 and further adjusted for other tumor markers.

^b P-value for heterogeneity test of marker expression positive vs. negative when alcohol evaluated as a categorical variable.

^c P-value for heterogeneity test of marker expression positive vs. negative when alcohol evaluated continuously as 11g/day.

Alcohol Consumption and Breast Cancer Risk According to Specific Subtypes of AR, ER and PR, Nurses' Health Study 1980 – 2006

Table 5

	No. of Cases	HR ^a	95%CI
AR+/ER+/PR+	1521	1.11	1.06, 1.17
AR+/ER+/PR–	247	1.09	0.97, 1.23
AR–/ER+/PR+	233	1.06	0.94, 1.19
R+/ER–/PR–	207	1.04	0.93, 1.18
AR–/ER+/PR–	53	1.04	0.89, 1.21
AR–/ER–/PR–	291	0.99	0.88, 1.12

^a Hazard ratios for each increment of per alcohol drink per day, adjusting for the same covariates as in footnote a in Table 3.